FDA Approves Afrezza for Pediatric Use: First Inhaled Insulin for Type 1 and Type 2 Diabetes in Children

Executive Brief

News Report

The News: FDA approves Afrezza for pediatric use, expanding treatment options for young patients with diabetes.
Clinical Win: Inhaled insulin provides a needle-free alternative, potentially improving adherence in pediatric patients.
Target Specialty: Endocrinology

Key Data at a Glance

Age Range Approved: 4 years and older
Indications: Type 1 and Type 2 Diabetes
Dosing Method: Tailored to individual needs

The FDA has approved Afrezza (insulin human) inhalation powder for use in children and adolescents with type 1 and type 2 diabetes, marking the first inhaled insulin approved for pediatric patients. This approval, announced in 2026, represents a significant advancement in diabetes management for younger patients who may benefit from a needle-free option.

Clinical Context

Diabetes is a chronic condition characterized by high blood sugar levels due to the body's inability to produce or effectively use insulin. Type 1 diabetes typically manifests in childhood or adolescence, requiring lifelong insulin therapy for survival. Type 2 diabetes, although more common in adults, is increasingly diagnosed in children, often linked to obesity and sedentary lifestyles. Traditional insulin delivery methods, such as injections, can be burdensome and distressing for young patients, leading to poor adherence and glycemic control. The introduction of Afrezza provides a needle-free alternative that may improve adherence and quality of life for pediatric patients. Afrezza is a rapid-acting inhaled insulin that allows for flexible dosing, potentially offering a more convenient option for managing blood glucose levels around mealtimes.

Key Findings

The FDA approval allows Afrezza to be used in children aged 4 years and older with type 1 or type 2 diabetes [1].
Afrezza is indicated for improving glycemic control in conjunction with long-acting insulin for type 1 diabetes and can be used alone or with other medications for type 2 diabetes [1].
Dosing for Afrezza is tailored to the individual, with recommendations based on the patient's blood glucose levels and dietary intake [1].
The inhaled insulin has been shown to provide rapid glucose control, with the onset of action occurring within minutes, making it suitable for use at mealtimes [1].

What This Means for Clinical Practice

The approval of Afrezza for pediatric use is a notable development for clinicians treating children and adolescents with diabetes. This inhaled insulin offers a viable alternative to traditional injection methods, which can be a source of anxiety and discomfort for young patients. Clinicians should consider incorporating Afrezza into treatment plans for eligible patients, particularly those who struggle with adherence to injection regimens. The rapid onset of action allows for more flexible dosing, which can be particularly beneficial in managing blood glucose levels during meals. However, it is essential to educate patients and their families about the proper use of the inhaler and monitor for potential adverse effects, including respiratory issues. As this new option becomes available, ongoing evaluation of its impact on patient adherence and glycemic control will be crucial in optimizing diabetes management in pediatric populations.

Clinical Perspective

Workflow: Clinicians should integrate Afrezza into treatment plans for eligible pediatric patients, emphasizing education on its use.

Economics: The introduction of a needle-free option may reduce costs associated with injection supplies and improve overall diabetes management.

Patient Outcomes: Enhanced adherence to treatment regimens can lead to better glycemic control and improved quality of life for children with diabetes.

Dr. Amit Desai, Endocrinology

References

FDA AccessData — AFREZZA® (insulin human) Inhalation Powder

FDA Approves Afrezza for Pediatric Use: First Inhaled Insulin for Type 1 and Type 2 Diabetes in Children

Executive Brief

Key Data at a Glance

Clinical Context

Key Findings

What This Means for Clinical Practice

Clinical Perspective

References

Get weekly drug updates for Endocrinology in your inbox.

Related Drug Updates

FDA Approves Foundayo for Obesity: New GLP-1 Pill Option

Semaglutide: Key Differences Between Ozempic and Wegovy for Diabetes and Weight Loss

FDA Approves Orforglipron for Chronic Weight Management in Adults with Obesity

Verified HCP Portal